ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation. (18th May 2022)

• Record Type: Journal Article
• Authors: Di Fusco, Stefania Angela; Gronda, Edoardo; Mocini, Edoardo; Lucà, Fabiana; Bisceglia, Irma; De Luca, Leonardo; Caldarola, Pasquale; Cipriani, Manlio; Corda, Marco; De Nardo, Alfredo; Francese, Giuseppina Maura; Napoletano, Cosimo; Navazio, Alessandro; Riccio, Carmine; Roncon, Loris; Tizzani, Emanuele; Nardi, Federico; Urbinati, Stefano; Valente, Serafina; Gulizia, Michele Massimo; Gabrielli, Domenico; Oliva, Fabrizio; Imperoli, Giuseppe; Colivicchi, Furio
• Is Part Of: European heart journal supplements. Volume 24(2022)Supplement C
• Page Start: C272
• Page End: C277
• Publication Date: 2022-05-18
• Subjects: Heart failure -- SGLT2 inhibitors -- Pharmacotherapy; Cardiology -- Periodicals; Cardiology -- Europe -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/suac017
• Languages: English
• ISSNs: 1520-765X

Abstract

Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduced ejection fraction (HFrEF) regardless of the presence of diabetes. Since these drugs have only recently been included among the four pillars of HFrEF treatment, cardiologists are still unfamiliar with their use in this setting. This article provides an up-to-date practical guide for the initiation and monitoring of patients treated with SGLT2 inhibitors.